Cardinal Health 10-Q 2025-09-30
CAH · CIK 721371 · Form 10-Q · Period ended September 30, 2025 · Filed October 30, 2025
Revenue rose 22.4% to $64.0 billion. Operating margin was 1.0%, against 1.1% a year earlier. Net income was $450 million.
8 sections, 182K characters. Original on sec.gov · ·
| Measure | Quarter ended Sep 30, 2025 | Quarter ended Sep 30, 2024 | Change |
|---|---|---|---|
| Revenue | $64.0B | $52.3B | +22.4% |
| Operating income | $668M | $568M | +17.6% |
| Net income | $450M | $416M | +8.2% |
| Diluted EPS | $1.88 | $1.70 | +10.6% |
| Free cash flow* | $865M | -$1.74B | n/a |
| Cash and equivalents | $4.59B | n/a | n/a |
| Operating margin* | 1.0% | 1.1% | -0.0 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
| Table of Contents |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
| ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2025
or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ________ to ________
Commission File Number: 1-11373
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
| Ohio | 31-0958666 | |||||||||||||||||||
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) | |||||||||||||||||||
| 7000 Cardinal Place | , | Dublin | , | Ohio | 43017 | |||||||||||||||
| (Address of principal executive offices) | (Zip Code) |
(614) 757-5000
(Registrant’s telephone number, including area code)
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common shares (without par value) | CAH | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☑ | Accelerated filer | ☐ | ||||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | ||||||||||||||
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
The number of the registrant’s common shares, without par value, outstanding as of October 24, 2025, was the following: 237,595,042.
| Cardinal Health Q1 Fiscal 2026 Form 10-Q |
Table of Contents
About Cardinal Health
Cardinal Health, Inc., an Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists, and manufacturers for integrated care coordination.
We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics. As used in this report, “we,” “our,” “us,” and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2026 and fiscal 2025 and to FY26 and FY25 are to the fiscal years ending or ended June 30, 2026 and June 30, 2025, respectively.
Forward-Looking Statements
This Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (this "Form 10-Q") (including any information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates, and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook, and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected, or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (“2025 Form 10-K”). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.
Non-GAAP Financial Measures
In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this Form 10-Q.
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 1 |
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
| MD&A | Overview |
Management's Discussion and Analysis of Financial Condition and Results of Operations
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at September 30, 2025 and June 30, 2025, and in our condensed consolidated statements of earnings and our condensed consolidated statements of cash flows for the three months ended September 30, 2025 and 2024. All comparisons presented are with respect to the prior-year period, unless stated otherwise. The discussion and analysis in this Form 10-Q should be read in conjunction with the MD&A included in our 2025 Form 10-K.
| 2 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
| MD&A | Overview |
Overview of Consolidated Results
Revenue
Revenue for the three months ended September 30, 2025 increased 22 percent to $64.0 billion from the prior-year quarter due to branded and specialty pharmaceutical sales growth from existing and new customers.
GAAP and Non-GAAP Operating Earnings
| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2025 | 2024 | Change | ||||||||||||||
| GAAP operating earnings | $ | 668 | $ | 568 | 18 | % | |||||||||||
| Restructuring and employee severance | 20 | 24 | |||||||||||||||
| Amortization and other acquisition-related costs | 104 | 74 | |||||||||||||||
| Acquisition-related cash and share-based compensation costs | 64 | — | |||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | 2 | (1) | |||||||||||||||
| Litigation (recoveries)/charges, net | — | (40) | |||||||||||||||
| Non-GAAP operating earnings | $ | 857 | $ | 625 | 37 | % |
The sum of the components and certain computations may reflect rounding adjustments.
GAAP operating earnings for the three months ended September 30, 2025 increased 18 percent to $668 million from the prior-year quarter primarily due to the impact of the acquisition of management services organization ("MSO") platforms and the acquisition of Advanced Diabetes Supply Group ("ADS") and increased contribution from branded and specialty pharmaceutical products, partially offset by acquisition-related cash and share-based compensation costs.
Non-GAAP operating earnings for the three months ended September 30, 2025 increased 37 percent to $857 million from the prior-year quarter primarily due to the impact of the acquisition of MSO platforms and the acquisition of ADS, increased contribution from branded and specialty pharmaceutical products, and growth from existing customers within the GMPD segment.
GAAP and Non-GAAP Diluted EPS
| Three Months Ended September 30, | |||||||||||||||||
| ($ per share) | 2025 (2) | 2024 (2) | Change | ||||||||||||||
| GAAP diluted EPS (1) | $ | 1.88 | $ | 1.70 | 11 | % | |||||||||||
| Restructuring and employee severance | 0.06 | 0.07 | |||||||||||||||
| Amortization and other acquisition-related costs | 0.31 | 0.22 | |||||||||||||||
| Acquisition-related cash and share-based compensation costs | 0.26 | — | |||||||||||||||
| Litigation (recoveries)/charges, net | 0.03 | (0.11) | |||||||||||||||
| Non-GAAP diluted EPS (1) | $ | 2.55 | $ | 1.88 | 36 | % |
The sum of the components and certain computations may reflect rounding adjustments.
(1) Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").
(2) The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."
For the three months ended September 30, 2025, GAAP and non-GAAP diluted EPS increased 11 percent to $1.88 and 36 percent to $2.55, respectively, from the prior-year quarter due to the factors impacting operating earnings in the preceding section, partially offset by increased interest expense.
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 3 |
| MD&A | Overview |
Significant Developments in Fiscal 2026 and Trends
Pharmaceutical and Specialty Solutions Segment
Solaris Health Acquisition
On August 12, 2025, we announced that we, through the Specialty Alliance, have entered into a definitive agreement to acquire Solaris Health for a purchase price of approximately $1.9 billion in cash, subject to certain adjustments. Solaris Health is the country's leading urology MSO and supports more than 750 providers across more than 250 practice locations in 14 states. In connection with the closing of this transaction, we will issue common units in the Specialty Alliance to certain physicians and management which are estimated to have a grant date fair value of approximately $500 million, a portion of which will be recognized as post-combination expense within acquisition-related cash and share-based compensation costs. We consolidate the results of the Specialty Alliance in our consolidated financial statements and report those consolidated results within our Pharma segment.
We intend to finance the acquisition with a combination of cash proceeds from the recent debt financing and cash on hand. See Note 5 of the "Notes to Condensed Consolidated Financial Statements" for additional information on the debt financing.
Management Service Organization Platforms
The performance of our MSO platforms, which consists of the Specialty Alliance and Navista, positively impacted the year-over-year comparison of Pharma segment profit during the three months ended September 30, 2025, primarily due to the impact of the acquisitions of GI Alliance ("GIA"), Urology America, and Integrated Oncology Network ("ION"). The Specialty Alliance is our multi-specialty MSO platform, which is primarily comprised of GIA, Urology America, and other gastroenterology- and urology-focused practices. Navista is our oncology MSO platform, which is primarily comprised of ION and other oncology-focused practices. Our ability to successfully provide physician practice support and management services, and to receive the value we expect to receive from our recent acquisitions of MSO platforms, depends upon a number of factors, including: the ability to develop or acquire and integrate appropriate practice management and support expertise; the ability to support recruitment, integration, and retention of sufficient numbers of local providers and staff; ensuring the alignment of interests between Cardinal Health and the physicians; the ability to successfully support negotiations with vendors, suppliers, and payors; the reimbursement and regulatory environment; and competition from other healthcare organizations.
Branded Pharmaceuticals
During the three months ended September 30, 2025, we saw increased demand for GLP-1 pharmaceuticals and our sales increased significantly. These increased sales positively impacted our Pharma segment and consolidated revenue for the three months ended September 30, 2025; however, increased GLP-1 sales did not meaningfully contribute to segment profit. Future demand for these medications is unpredictable and our ability to meet demand may be impacted by supply constraints. Additionally, the recently issued Executive Order titled “Delivering Most-Favored Nation Prescription Drug Pricing to American Patients” may impact sales or profitability of branded pharmaceutical products, including GLP-1 products; however, the extent of the impact is uncertain and may vary depending on the timeline for implementation and the extent of any price reductions. It is also possible that the adoption of the One Big Beautiful Bill Act ("OBBBA") could reduce participation in Medicare and Medicaid programs, resulting in a change in utilization of the healthcare system. This may adversely affect demand for our products and services; however, the extent of any reduction is unpredictable.
Generics Program
The performance of our Pharma segment generics program positively impacted the year-over-year comparison of Pharma segment profit during the three months ended September 30, 2025. The Pharma segment generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes, the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health"), and generic pharmaceutical contract manufacturing and sourcing costs.
The frequency, timing, magnitude, and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, generic pharmaceutical manufacturer pricing changes, and generic pharmaceutical contract manufacturing and sourcing costs all impact Pharma segment profit and are subject to risks and uncertainties. These risks and uncertainties may impact Pharma segment profit and consolidated operating earnings during the remainder of fiscal 2026 and beyond.
| 4 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
| MD&A | Overview |
Global Medical Products and Distribution Segment
Volumes
We experienced Cardinal Health brand medical products sales growth during the three months ended September 30, 2025 and expect further growth during the remainder of fiscal 2026 and beyond. The timing, magnitude, and profit impact of this anticipated sales growth is subject to risks and uncertainties, which may impact GMPD segment profit.
Tariffs
Recent U.S. tariffs imposed or threatened to be imposed on goods, materials, and products imported into the United States from countries where we do business and any retaliatory or responsive actions taken by such countries have resulted in us incurring substantial additional costs to source products and materials, directly and indirectly, from affected countries, and are requiring us to raise prices on certain products and seek alternative sources of supply. It is also possible that we could experience supply disruptions or shortages as a result of tariffs or other protective measures.
We have taken action to reduce the potential impact of tariffs on our costs; however, at this time, the countries that will be subject to tariffs and the tariff rate that may be imposed on each country is uncertain and dynamic and we do not expect to be able to establish alternative sources of supply or otherwise mitigate the potential impact of tariffs on all of the products that we source, manufacture, or distribute. If we are not able to offset the impact of tariffs through price increases or otherwise mitigate the impacts, our financial results could be negatively impacted. Additionally, if tariffs are modified in the future, or our preliminary information is incorrect regarding their impact, we may not be able to respond to such changes adequately or in a timely manner and our financial results could be negatively impacted. Furthermore, if our competitors do not increase prices, or increase prices to a lesser extent than we do, or are able to offset the impact of tariffs through other actions, our competitive and financial position may be adversely affected.
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 5 |
| MD&A | Results of Operations |
Results of Operations
Revenue



| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2025 | 2024 | Change | ||||||||||||||
| Pharmaceutical and Specialty Solutions | $ | 59,205 | $ | 47,990 | 23 | % | |||||||||||
| Global Medical Products and Distribution | 3,184 | 3,123 | 2 | % | |||||||||||||
| Other | 1,641 | 1,186 | 38 | % | |||||||||||||
| Total segment revenue | 64,030 | 52,299 | 22 | % | |||||||||||||
| Corporate | (21) | (22) | N.M. | ||||||||||||||
| Total revenue | $ | 64,009 | $ | 52,277 | 22 | % |
Pharmaceutical and Specialty Solutions
Pharma segment revenue increased 23 percent to $59.2 billion from the prior-year quarter primarily due to branded and specialty pharmaceutical sales growth from existing and new customers.
Global Medical Products and Distribution
GMPD segment revenue increased 2 percent to $3.2 billion from the prior-year quarter primarily due to volume growth from existing customers.
Other
Other segment revenue increased 38 percent to $1.6 billion from the prior-year quarter due to growth across at-Home Solutions (including the acquisition of ADS), Nuclear and Precision Health Solutions, and OptiFreight® Logistics.
Cost of Products Sold
Cost of products sold increased 22 percent to $61.7 billion from the prior-year quarter due to the factors affecting the changes in revenue and gross margin.
| 6 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
| MD&A | Results of Operations |
Gross Margin


| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2025 | 2024 | Change | ||||||||||||||
| Gross margin | $ | 2,319 | $ | 1,902 | 22 | % |
Gross margin increased 22 percent to $2.3 billion from the prior-year quarter primarily due to the acquisition of MSO platforms and the acquisition of ADS and the increased contribution from branded pharmaceutical and specialty pharmaceutical products.
Gross margin rate was relatively flat compared to the prior-year quarter with impact of the unfavorable changes in product mix for the Pharma segment mostly offset by the beneficial gross margin rates due to the acquisition of MSO platforms. The changes in product mix were primarily driven by increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate.
Distribution, Selling, General, and Administrative ("SG&A") Expenses
| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2025 | 2024 | Change | ||||||||||||||
| SG&A expenses | $ | 1,461 | $ | 1,277 | 14 | % |
SG&A expenses increased 14 percent to $1.5 billion from the prior-year quarter primarily due to the inclusion of the acquisition of MSO platforms and the acquisition of ADS.
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 7 |
| MD&A | Results of Operations |
Segment Profit
We evaluate segment performance based on segment profit, among other measures. See Note 12 of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.
| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2025 | 2024 | Change | ||||||||||||||
| Pharmaceutical and Specialty Solutions | $ | 667 | $ | 530 | 26 | % | |||||||||||
| Global Medical Products and Distribution | 46 | 8 | N.M. | ||||||||||||||
| Other | 166 | 104 | 60 | % | |||||||||||||
| Total segment profit | 879 | 642 | 37 | % | |||||||||||||
| Corporate | (211) | (74) | N.M. | ||||||||||||||
| Total consolidated operating earnings | $ | 668 | $ | 568 | 18 | % |
Pharmaceutical and Specialty Solutions
Pharma segment profit increased 26 percent to $667 million from the prior-year quarter primarily due to increased contribution from branded and specialty pharmaceutical products, the acquisition of MSO platforms, and the performance of our generics program.
Global Medical Products and Distribution
GMPD segment profit increased to $46 million from the prior-year quarter primarily due to growth from existing customers.
Other
Other segment profit increased 60 percent to $166 million from the prior-year quarter primarily due to the performance of all of at-Home Solutions (including the acquisition of ADS), OptiFreight® Logistics, and Nuclear and Precision Health Solutions.
Corporate
The changes in Corporate during the three months ended September 30, 2025 are due to the factors discussed in the "Other Components of Consolidated Operating Earnings" section that follows.
| 8 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
| MD&A | Results of Operations |
Other Components of Consolidated Operating Earnings
In addition to revenue, gross margin, and SG&A expenses discussed previously, consolidated operating earnings were impacted by the following:
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2025 | 2024 | |||||||||
| Restructuring and employee severance | $ | 20 | $ | 24 | |||||||
| Amortization and other acquisition-related costs | 104 | 74 | |||||||||
| Acquisition-related cash and share-based compensation costs | 64 | — | |||||||||
| Impairments and (gain)/loss on disposal of assets, net | 2 | (1) | |||||||||
| Litigation (recoveries)/charges, net | — | (40) |
Restructuring and Employee Severance
During the three months ended September 30, 2025 and 2024, restructuring and employee severance costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and certain initiatives to rationalize our manufacturing operations.
Amortization and Other Acquisition-Related Costs
Amortization of acquisition-related intangible assets was $87 million and $68 million for the three months ended September 30, 2025 and 2024, respectively.
Transaction and integration costs associated with acquisitions were $17 million for the three months ended September 30, 2025.
Acquisition-related cash and share-based compensation costs
Acquisition-related cash and share-based compensation costs were $64 million for the three months ended September 30, 2025, primarily resulting from the acquisition of GIA.
Litigation (Recoveries)/Charges, Net
During the three months ended September 30, 2024, we recognized income of $43 million for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff.
Earnings Before Income Taxes
In addition to the items discussed above, earnings before income taxes was impacted by the following:
| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2025 | 2024 | Change | ||||||||||||||
| Other (income)/expense, net | $ | (10) | $ | (5) | N.M. | ||||||||||||
| Interest expense, net | 80 | 32 | N.M. | ||||||||||||||
Interest Expense, Net
Interest expense, net, increased to $80 million from the prior-year quarter primarily due to the additional debt financing for our recent acquisitions.
Provision for Income Taxes
During the three months ended September 30, 2025 and 2024, the effective tax rate was 24.1 percent and 23.0 percent, respectively. See Note 7 of the “Notes to Condensed Consolidated Financial Statements” for additional information.
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 9 |
| MD&A | Liquidity and Capital Resources |
Liquidity and Capital Resources
We currently believe that, based on available capital resources and projected operating cash flow, we have adequate capital resources to fund our operations and expected future cash needs as described below. In addition to those disclosed, if we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.
Cash and Equivalents
Our cash and equivalents balance was $4.6 billion at September 30, 2025 compared to $3.9 billion at June 30, 2025.
During the three months ended September 30, 2025, net cash provided by operating activities was $1.0 billion, which includes the impact of payments totaling $403 million related to the opioid litigation.
During the three months ended September 30, 2025, we deployed $500 million for debt repayment, $375 million for share repurchases, $129 million for dividends, and $108 million for capital expenditures. In addition, we issued new long-term debt and received net proceeds of approximately $1.0 billion to fund a portion of the consideration payable in connection with the Solaris Health acquisition and for general purposes.
At September 30, 2025, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.
Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, payments to vendors, and tax payments in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.
The cash and equivalents balance at September 30, 2025 included $596 million of cash held by subsidiaries outside of the United States.
Other Financing Arrangements and Financial Instruments
Credit Facilities and Commercial Paper
In addition to cash and equivalents and operating cash flow, other sources of liquidity at September 30, 2025 include a $3.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility that expires in February 2028 and a $1.0 billion 364-Day revolving credit facility that expired in October 2025. We also have a $1.0 billion committed receivables sales facility through September 2028. At September 30, 2025, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.
In September 2025, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 28, 2028.
In October 2025, we renewed the 364-Day revolving credit facility, under which we have access to $1.0 billion of committed liquidity through October 2026.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of September 30, 2025, we were in compliance with this financial covenant.
Long-Term Debt and Other Short-Term Borrowings
We had total long-term obligations, including the current portion and other short-term borrowings, of $9.0 billion and $8.5 billion at September 30, 2025 and June 30, 2025, respectively.
In August 2025, we issued additional debt, with the aggregate principal amount of $1.0 billion, to fund a portion of the consideration payable in connection with the Solaris Health acquisition and for general purposes. The notes issued are $600 million aggregate principal amount of 4.5% Notes that mature on September 15, 2030 and $400 million aggregate principal amount of 5.15% Notes that mature on September 15, 2035. The proceeds of the notes issued, net of discounts, premiums, and debt issuance costs, were approximately $1.0 billion.
During the three months ended September 30, 2025, we repaid the full principal of $500 million of the 3.75% Notes due 2025 at maturity with available cash.
| 10 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
| MD&A | Liquidity and Capital Resources |
Capital Deployment
Opioid Litigation Settlements
We had $4.3 billion accrued at September 30, 2025 related to certain national opioid litigation settlements, as further described within Note 6 of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the remaining payment amounts to occur through 2038. During the three months ended September 30, 2025, we made our fifth annual payment of $366 million under National Opioid Settlement Agreement ("the NOSA") and other payments of $37 million related to the opioid litigation. The amounts of future annual payments under the NOSA may differ from the payments that we have already made.
Capital Expenditures
Capital expenditures during the three months ended September 30, 2025 and 2024 were $108 million and $90 million, respectively.
Dividends
On each of May 5, 2025 and August 15, 2025, our Board of Directors approved a quarterly dividend of $0.5107 per share, or $2.04 per share on an annualized basis, which were paid on July 15, 2025 and October 15, 2025 to shareholders of record on July 1, 2025 and October 1, 2025, respectively.
Share Repurchases
During the three months ended September 30, 2025, we deployed $375 million for repurchases of our common shares under an accelerated share repurchase ("ASR") program. We funded the repurchases with available cash. The ASR program will conclude by October 31, 2025 and reduce the amount remaining under our existing share repurchase authorization to less than $2.4 billion. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
Solaris Health Acquisition
On August 12, 2025, we announced that we, through the Specialty Alliance, have entered into a definitive agreement to acquire Solaris Health, a urology MSO, for a purchase price of approximately $1.9 billion in cash, subject to certain adjustments. In connection with the closing of this transaction, we will issue common units in the Specialty Alliance to certain physicians and management which are estimated to have a grant date fair value of approximately $500 million, a portion of which will be recognized as post-combination expense. See Note 2 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 11 |
| MD&A | Other Items |
Other Items
The MD&A in the 2025 Form 10-K addresses our contractual obligations and cash requirements, as of and for the fiscal year ended June 30, 2025. Other than the considerations noted above in connection with the planned acquisition and our debt issuance, there have been no subsequent material changes outside of the ordinary course of business to those items. See Note 2 and Note 5 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
Critical Accounting Policies and Sensitive Accounting Estimates
Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management’s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Estimates are inherently uncertain, therefore actual results may differ, including due to the risks discussed in "Risk Factors" and other risks discussed in the 2025 Form 10-K and our other filings with the SEC since June 30, 2025. There have been no material changes to our critical accounting estimates since the filing of our 2025 Form 10-K.
| 12 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
| Explanation and Reconciliation of Non-GAAP Financial Measures |
Explanation and Reconciliation of Non-GAAP Financial Measures
The "Overview of Consolidated Results" section within MD&A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.
In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.
Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:
-
LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. We did not recognize any LIFO charges or credits during the periods presented.
-
State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.
-
Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance, and realigning operations.
-
Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets and amortization as a result of basis differences in equity method investments are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current, and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity, and size of acquisitions.
-
Acquisition-related cash and share-based compensation costs are incurred in connection with contingent cash payments or the issuance of share-based payment awards, which include service requirements, as a part of certain physician practice acquisitions. These costs include fair value adjustments for liability-classified awards. These costs are excluded because they are unrelated to the underlying operating results of our business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. In addition, the magnitude of these expenses is significantly impacted by the timing and size of the acquisitions of physician practices.
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 13 |
| Explanation and Reconciliation of Non-GAAP Financial Measures |
-
Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current, and forecasted financial results.
-
Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.
Definitions
Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.
Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.
Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.
Non-GAAP net earnings attributable to non-controlling interests: net earnings attributable to non-controlling interests excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, each net of tax.
Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, each net of tax.
Non-GAAP effective tax rate: provision for income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, divided by (earnings before income taxes adjusted for the items above).
Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.
| 14 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
| Explanation and Reconciliation of Non-GAAP Financial Measures |
GAAP to Non-GAAP Reconciliations
| Operating Earnings | Operating Earnings Growth Rate | Earnings Before Income Taxes | Provision for Income Taxes | Net Earnings Attributable to Non-Controlling Interests | Net Earnings****1 | Net Earnings****1 Growth Rate | Diluted EPS****1 | Diluted EPS****1 Growth Rate | |||||||||||||||||||||||||||||||||
| (in millions, except per common share amounts) | Three Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||
| GAAP | $ | 668 | 18 | % | $ | 598 | $ | 144 | $ | (4) | $ | 450 | 8 | % | $ | 1.88 | 11 | % | |||||||||||||||||||||||
| Restructuring and employee severance | 20 | 20 | 5 | 15 | 0.06 | ||||||||||||||||||||||||||||||||||||
| Amortization and other acquisition-related costs | 104 | 104 | 30 | 74 | 0.31 | ||||||||||||||||||||||||||||||||||||
| Acquisition-related cash and share-based compensation costs | 64 | 64 | 1 | 63 | 0.26 | ||||||||||||||||||||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | 2 | 2 | 1 | 1 | — | ||||||||||||||||||||||||||||||||||||
| Litigation (recoveries)/charges, net | — | — | (8) | 8 | 0.03 | ||||||||||||||||||||||||||||||||||||
| Non-GAAP | $ | 857 | 37 | % | $ | 788 | $ | 173 | $ | (4) | $ | 611 | 33 | % | $ | 2.55 | 36 | % | |||||||||||||||||||||||
| Three Months Ended September 30, 2024 | |||||||||||||||||||||||||||||||||||||||||
| GAAP | $ | 568 | N.M. | $ | 541 | $ | 124 | $ | (1) | $ | 416 | N.M. | $ | 1.70 | N.M. | ||||||||||||||||||||||||||
| Restructuring and employee severance | 24 | 24 | 6 | 18 | 0.07 | ||||||||||||||||||||||||||||||||||||
| Amortization and other acquisition-related costs | 74 | 74 | 20 | 54 | 0.22 | ||||||||||||||||||||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | (1) | (1) | — | (1) | — | ||||||||||||||||||||||||||||||||||||
| Litigation (recoveries)/charges, net | (40) | (40) | (12) | (28) | (0.11) | ||||||||||||||||||||||||||||||||||||
| Non-GAAP | $ | 625 | 12 | % | $ | 598 | $ | 138 | $ | (1) | $ | 460 | 7 | % | $ | 1.88 | 9 | % |
1 Attributable to Cardinal Health, Inc.
The sum of the components and certain computations may reflect rounding adjustments.
We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 15 |
| Other |
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the quantitative and qualitative market risk disclosures included in the 2025 Form 10-K since the end of fiscal 2025 through September 30, 2025.
Item 4. Controls and Procedures
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of September 30, 2025. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of September 30, 2025, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 16 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
| Other |
Legal Proceedings
The legal proceedings described in Note 6 of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.
Item 1A. Risk Factors
Risk Factors
You should carefully consider the information in this Form 10-Q and the risk factors discussed in "Risk Factors" and other risks discussed in the 2025 Form 10-K and our filings with the SEC since June 30, 2025. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.
Changes to the U.S. healthcare environment may not
be favorable to us.
Over a number of years, the U.S. healthcare industry has undergone significant changes designed to increase access to medical care, improve safety and patient outcomes, contain costs, and increase efficiencies. These changes include a general decline in Medicare and Medicaid reimbursement levels, efforts by healthcare insurance companies to limit or reduce payments to pharmacies and providers, the basis for payments beginning to transition from a fee-for-service model to value-based payments and risk-sharing models, and the industry shifting away from traditional healthcare venues like hospitals and into clinics, physician offices, and patients’ homes.
We expect the U.S. healthcare industry to continue to change significantly in the future. Possible changes include changes in legislation or regulations governing prescription pharmaceutical pricing (including recently proposed changes to the definition, implementation and documentation of the Bona Fide Services Fees excluded from the calculation of the Average Sales Price of Medicare Part B drugs), healthcare services, U.S.-based medical product manufacturing, mandated benefits, efforts to promote increased transparency in the pharmaceutical supply chain, drug shortages, further reduction of or limitations on governmental funding at the state or federal level, or efforts by healthcare insurance companies to further limit payments for products and services. Federal, state, and local governmental entities have also continued to increase their scrutiny of the U.S. healthcare market.
Uncertainty surrounding possible changes to the healthcare environment, including changes to regulatory enforcement
priorities, may directly or indirectly adversely affect us. The recently issued Executive Order titled "Delivering Most-Favored Nation Prescription Drug Pricing to American Patients" may impact the sales or profitability of branded pharmaceutical products; however, the extent of the impact may vary depending on the timeline for implementation and the number of pharmaceutical drugs that are impacted. Additionally, it is possible that the adoption of the One Big Beautiful Bill Act ("OBBBA") could reduce participation in Medicare and Medicaid programs, resulting in a change in utilization of the healthcare system. This may adversely affect demand for our products and services and could have an effect on our results of operations and financial condition.
Private challenges to government healthcare policy may also have an adverse impact on our business. For example, the federal 340B drug pricing program requires pharmaceutical manufacturers to offer discounts on certain drugs purchased by covered entities, and some of our Pharma segment customers are covered entities or contract pharmacies for covered entities. Over a dozen pharmaceutical manufacturers have restricted sales under the 340B drug pricing program to a limited number of contract pharmacies. These practices are the subject of ongoing litigation; however, if manufacturers continue this practice and if courts uphold this practice, our customers may be adversely impacted, which could adversely impact our business.
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 17 |
| Other |
Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
| Period | Total Number of Shares Purchased (1,2) | Average Price Paid per Share (2) | Total Number of Shares Purchased as Part of Publicly Announced Programs (2,3) | Approximate Dollar Value of Shares That May Yet be Purchased Under the Program (3) (in millions) | |||||||||||||||||||
| July 2025 | 11 | $ | 159.70 | — | $ | 2,743 | |||||||||||||||||
| Aug 2025 | 2,025,391 | 148.12 | 2,025,385 | 2,443 | |||||||||||||||||||
| Sept 2025 | 31 | 150.34 | — | 2,443 | |||||||||||||||||||
| Total | 2,025,433 | $ | 148.12 | 2,025,385 | $ | 2,443 |
(1)Reflects 11, 6, and 31 common shares purchased in July, August, and September 2025, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.
(2)On August 13, 2025, we entered into an ASR program to purchase common shares for an aggregate purchase price of $375 million and received an initial delivery of 2.0 million common shares using a reference price of $148.12. The ASR program will conclude by October 31, 2025. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(3)On June 7, 2023, our Board of Directors approved a new $3.5 billion share repurchase program, which will expire on December 31, 2027. As of September 30, 2025, we had $2.4 billion authorized for share repurchases remaining under this program. The ASR program is expected to reduce the amount remaining under our existing share repurchase authorization to less than $2.4 billion when concluded.
Item 5. Other Information
Other Information
Rule 10b5-1 Plan Adoptions and Modifications
During the three months ended September 30, 2025, no director or officer adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule10b5-1 trading arrangement" as each term is defined in Item 408 of Regulation S-K under the Exchange Act.
| 18 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
Item 1. Financial Statements
| Financial Statements |
Condensed Consolidated Statements of Earnings
(Unaudited)
| Three Months Ended September 30, | |||||||||||
| (in millions, except per common share amounts) | 2025 | 2024 | |||||||||
| Revenue | $ | 64,009 | $ | 52,277 | |||||||
| Cost of products sold | 61,690 | 50,375 | |||||||||
| Gross margin | 2,319 | 1,902 | |||||||||
| Operating expenses: | |||||||||||
| Distribution, selling, general and administrative expenses | 1,461 | 1,277 | |||||||||
| Restructuring and employee severance | 20 | 24 | |||||||||
| Amortization and other acquisition-related costs | 104 | 74 | |||||||||
| Acquisition-related cash and share-based compensation costs | 64 | — | |||||||||
| Impairments and (gain)/loss on disposal of assets, net | 2 | (1) | |||||||||
| Litigation (recoveries)/charges, net | — | (40) | |||||||||
| Operating earnings | 668 | 568 | |||||||||
| Other (income)/expense, net | (10) | (5) | |||||||||
| Interest expense, net | 80 | 32 | |||||||||
| Earnings before income taxes | 598 | 541 | |||||||||
| Provision for income taxes | 144 | 124 | |||||||||
| Net earnings | 454 | 417 | |||||||||
| Less: Net earnings attributable to noncontrolling interests | (4) | (1) | |||||||||
| Net earnings attributable to Cardinal Health, Inc. | $ | 450 | $ | 416 | |||||||
| Earnings per common share attributable to Cardinal Health, Inc.: | |||||||||||
| Basic | $ | 1.89 | $ | 1.71 | |||||||
| Diluted | 1.88 | 1.70 | |||||||||
| Weighted-average number of common shares outstanding: | |||||||||||
| Basic | 238 | 243 | |||||||||
| Diluted | 239 | 245 | |||||||||
| Cash dividends declared per common share | $ | 0.5107 | $ | 0.5056 |
See notes to condensed consolidated financial statements.
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 19 |
| Financial Statements |
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2025 | 2024 | |||||||||
| Net earnings | $ | 454 | $ | 417 | |||||||
| Other comprehensive income/(loss): | |||||||||||
| Foreign currency translation adjustments and other | (4) | 5 | |||||||||
| Net unrealized gain/(loss) on derivative instruments, net of tax | — | 7 | |||||||||
| Total other comprehensive income/(loss), net of tax | (4) | 12 | |||||||||
| Total comprehensive income | 450 | 429 | |||||||||
| Less: comprehensive income attributable to noncontrolling interests | (4) | (1) | |||||||||
| Total comprehensive income attributable to Cardinal Health, Inc. | $ | 446 | $ | 428 |
See notes to condensed consolidated financial statements.
| 20 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
| Financial Statements |
Condensed Consolidated Balance Sheets
| (in millions) | September 30, 2025 | June 30, 2025 | |||||||||
| Assets | (Unaudited) | ||||||||||
| Current assets: | |||||||||||
| Cash and equivalents | $ | 4,593 | $ | 3,874 | |||||||
| Trade receivables, net | 13,770 | 13,242 | |||||||||
| Inventories, net | 17,559 | 16,831 | |||||||||
| Prepaid expenses and other | 2,602 | 2,414 | |||||||||
| Assets held for sale | 13 | 12 | |||||||||
| Total current assets | 38,537 | 36,373 | |||||||||
| Property and equipment, net | 2,831 | 2,858 | |||||||||
| Goodwill and other intangibles, net | 12,110 | 12,177 | |||||||||
| Other assets | 1,750 | 1,714 | |||||||||
| Total assets | $ | 55,228 | $ | 53,122 | |||||||
| Liabilities and Shareholders’ Deficit | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 36,860 | $ | 34,713 | |||||||
| Current portion of long-term obligations and other short-term borrowings | 52 | 550 | |||||||||
| Other accrued liabilities | 3,356 | 3,634 | |||||||||
| Total current liabilities | 40,268 | 38,897 | |||||||||
| Long-term obligations, less current portion | 8,980 | 7,977 | |||||||||
| Deferred income taxes and other liabilities | 8,711 | 8,882 | |||||||||
| Shareholders’ deficit: | |||||||||||
| Preferred shares, without par value: | |||||||||||
| Authorized—500 thousand shares, Issued—none | — | — | |||||||||
| Common shares, without par value: | |||||||||||
| Authorized—755 million shares, Issued—271 million shares at September 30, 2025 and June 30,2025 | 2,746 | 2,956 | |||||||||
| Retained earnings | 1,116 | 783 | |||||||||
| Common shares in treasury, at cost: 33 million shares and 32 million shares at September 30, 2025 and June 30, 2025, respectively | (6,582) | (6,365) | |||||||||
| Accumulated other comprehensive loss | (159) | (155) | |||||||||
| Total Cardinal Health, Inc. shareholders' deficit | (2,879) | (2,781) | |||||||||
| Noncontrolling interests | 148 | 147 | |||||||||
| **Total shareholders’ defici |
Showing the first 8K of 102K characters. Open the full section
Item 6. Exhibits
| Exhibits |
Exhibits
Cardinal Health Website
Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases, SEC filings, and certain other information on its website.
| 38 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |
| Form 10-Q Cross Reference Index |
Form 10-Q Cross Reference Index
| Item Number | Page | |||||||
| Part I. Financial Information | ||||||||
| Item 1 | Financial Statements | 19 | ||||||
| Item 2 | Management's Discussion and Analysis of Financial Condition and Results of Operations | 2 | ||||||
| Item 3 | Quantitative and Qualitative Disclosures about Market Risk | 16 | ||||||
| Item 4 | Controls and Procedures | 16 | ||||||
| Part II. Other Information | ||||||||
| Item 1 | Legal Proceedings | 17 | ||||||
| Item 1A | Risk Factors | 17 | ||||||
| Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds | 18 | ||||||
| Item 3 | Defaults Upon Senior Securities | N/A | ||||||
| Item 4 | Mine Safety Disclosures | N/A | ||||||
| Item 5 | Other Information | 18 | ||||||
| Item 6 | Exhibits | 38 | ||||||
| Signatures | 40 |
| N/A | Not applicable |
| Cardinal Health | Q1 Fiscal 2026 Form 10-Q | 39 |
| Additional Information |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Cardinal Health, Inc. | ||||||||
| Date: | October 30, 2025 | /s/ JASON M. HOLLAR | ||||||
| Jason M. Hollar | ||||||||
| Chief Executive Officer | ||||||||
| /s/ AARON E. ALT | ||||||||
| Aaron E. Alt | ||||||||
| Chief Financial Officer |
| 40 | Cardinal Health | Q1 Fiscal 2026 Form 10-Q |